HUE043514T2 - Heterociklusos vegyület - Google Patents

Heterociklusos vegyület

Info

Publication number: HUE043514T2
Authority: HU; Hungary
Prior art keywords: heterocyclic compound; heterocyclic; compound
Prior art date: 2010-02-17

Application number

HUE11744685A

Other languages

English (en)

Inventor

Misaki Homma

Toru Miyazaki

Yuya Oguro

Osamu Kurasawa

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-17

Filing date

2011-02-16

Publication date

2019-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE043514(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-16 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2019-08-28 Publication of HUE043514T2 publication Critical patent/HUE043514T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

HUE11744685A 2010-02-17 2011-02-16 Heterociklusos vegyület HUE043514T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2010031899		2010-02-17
JP2010131950		2010-06-09

Publications (1)

Publication Number	Publication Date
HUE043514T2 true HUE043514T2 (hu)	2019-08-28

Family

ID=44482985

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE11744685A HUE043514T2 (hu)	2010-02-17	2011-02-16	Heterociklusos vegyület

Country Status (37)

Country	Link
US (6)	US8722660B2 (hu)
EP (2)	EP3533797B1 (hu)
JP (1)	JP5689454B2 (hu)
KR (1)	KR101735868B1 (hu)
CN (1)	CN102844320B (hu)
AU (1)	AU2011216404B2 (hu)
BR (1)	BR112012020311B1 (hu)
CA (1)	CA2790284C (hu)
CL (1)	CL2012002250A1 (hu)
CO (1)	CO6592104A2 (hu)
CR (1)	CR20120448A (hu)
CY (1)	CY1121792T1 (hu)
DK (1)	DK2540728T3 (hu)
DO (1)	DOP2012000224A (hu)
EA (1)	EA020724B1 (hu)
EC (1)	ECSP12012160A (hu)
ES (1)	ES2733221T3 (hu)
GE (1)	GEP20146202B (hu)
HR (1)	HRP20190947T1 (hu)
HU (1)	HUE043514T2 (hu)
IL (1)	IL221442A0 (hu)
LT (1)	LT2540728T (hu)
MA (1)	MA34064B1 (hu)
ME (1)	ME03410B (hu)
MX (1)	MX353500B (hu)
MY (1)	MY164776A (hu)
NZ (1)	NZ602089A (hu)
PE (1)	PE20130184A1 (hu)
PH (1)	PH12012501650B1 (hu)
PL (1)	PL2540728T3 (hu)
PT (1)	PT2540728T (hu)
RS (1)	RS58796B1 (hu)
SG (1)	SG183304A1 (hu)
SI (1)	SI2540728T1 (hu)
SM (1)	SMT201900385T1 (hu)
TN (1)	TN2012000401A1 (hu)
WO (1)	WO2011102399A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103153300A (zh) *	2010-08-11	2013-06-12	米伦纽姆医药公司	杂芳基化合物和其用途
JP6569908B2 (ja)	2014-01-31	2019-09-04	カルナバイオサイエンス株式会社	抗がん剤組成物
TW201620879A (zh)	2014-04-28	2016-06-16	杜邦股份有限公司	除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) *	2014-05-05	2019-01-08	Signalrx Pharmaceuticals, Inc.	Heterocyclic compound classes for signaling modulation
CA3007840C (en)	2015-12-07	2020-09-15	Zymergen Inc.	Microbial strain improvement by a htp genomic engineering platform
AU2016378723B2 (en)	2015-12-22	2021-09-30	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
CA3016708A1 (en) *	2016-03-28	2017-10-05	Takeda Pharmaceutical Company Limited	Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
EA035560B1 (ru) *	2016-07-28	2020-07-07	Такеда Фармасьютикал Компани Лимитед	Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
CA3042929A1 (en)	2016-11-08	2018-05-17	Cancer Research Technology Limited	Pyrimidinone derivatives as cdc7 inhibitors
US11155879B2 (en)	2017-03-01	2021-10-26	Takeda Pharmaceutical Company Limited	Method of predicting effects of CDC7 inhibitor
CN112409373A (zh) *	2017-05-21	2021-02-26	南京正济医药研究有限公司	作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
MX2019014875A (es)	2017-06-21	2021-01-29	SHY Therapeutics LLC	Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
CA3095264A1 (en) *	2018-04-02	2019-10-10	Takeda Pharmaceutical Company Limited	Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TWI846703B (zh)	2018-06-19	2024-07-01	日商武田藥品工業股份有限公司	癌症治療方法
AU2019305828A1 (en)	2018-07-19	2021-01-28	Takeda Pharmaceutical Company Limited	Pharmaceutical compositions with a CDC7 inhibitor
KR20220027883A (ko) *	2019-05-30	2022-03-08	치아타이 티안큉 파마수티컬 그룹 주식회사	Cdc7 억제제로서의 테트라사이클릭 화합물
CA3146792A1 (en) *	2019-07-19	2021-01-28	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
WO2021032170A1 (zh) *	2019-08-20	2021-02-25	南京明德新药研发有限公司	用作Cdc7抑制剂的四并环类化合物
WO2021113492A1 (en)	2019-12-06	2021-06-10	Schrödinger, Inc.	Cyclic compounds and methods of using same
WO2022055963A1 (en) *	2020-09-10	2022-03-17	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
EP4253388A1 (en) *	2020-11-30	2023-10-04	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Salt form used as cdc7 inhibitor and crystal form thereof
CN112661770B (zh) *	2020-12-24	2022-11-08	南京正济医药研究有限公司	一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
US20240173323A1 (en)	2021-02-08	2024-05-30	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
TW202300150A (zh) *	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
EP4416156A1 (en) *	2021-10-13	2024-08-21	Remix Therapeutics Inc.	Compounds and methods for modulating nucleic acid splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
JP2002105081A (ja)	2000-07-28	2002-04-10	Nikken Chem Co Ltd	新規チオフェンニ環化合物
JPWO2002026745A1 (ja)	2000-09-29	2004-02-05	日本曹達株式会社	チエノピリミジン化合物とその塩並びに製造方法
US6503914B1 (en)	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
EP1383771A1 (en)	2001-04-20	2004-01-28	Vertex Pharmaceuticals Incorporated	9-deazaguanine derivatives as inhibitors of gsk-3
DE60304718T2 (de)	2002-08-06	2007-04-26	Astrazeneca Ab	Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
DK1641803T3 (da) *	2003-06-11	2009-06-29	Xention Ltd	Thienopyrimidinderivater som kaliumkanalinhibitorer
US20050032869A1 (en) *	2003-07-08	2005-02-10	Pharmacia Italia S.P.A.	Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en)	2003-08-08	2007-10-09	Pfizer Italia S.R.L.	Pyrimidylpyrrole derivatives active as kinase inhibitors
EP1660475B1 (en)	2003-08-08	2008-05-28	Pfizer Italia S.r.l.	Pyrimidylpyrrole derivatives active as kinase inhibitors
MXPA06010520A (es) *	2004-03-30	2007-03-26	Chiron Corp	Derivados de tiofeno sustituidos como agentes anticancerosos.
EP2520652B1 (en)	2004-04-09	2015-06-10	Genecare Research Institute Co., Ltd	Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1856128A4 (en)	2005-01-19	2009-12-23	Merck & Co Inc	MITOTIC INHIBITORS OF KINESIN
EP1907398A1 (en)	2005-07-15	2008-04-09	AstraZeneca AB	Therapeutic agents
BRPI0614974A2 (pt)	2005-08-30	2010-12-14	Asahi Kasei Pharma Corp	composto, medicamento, inibidor da fosforilaÇço da cadeia leve regulatària da miosina, inibidor da via rho/rho quinase, e, mÉtodo para tratamento terapÊutico e/ou profilÁtico de glaucoma
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US20070142414A1 (en)	2005-12-16	2007-06-21	Pharmacia Italia S.P.A.	N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) *	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007102679A1 (en)	2006-03-06	2007-09-13	Je Il Pharmaceutical Co., Ltd.	Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008082839A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) *	2006-12-29	2009-01-29	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
WO2008094909A2 (en)	2007-01-29	2008-08-07	Xenon Pharmaceuticals Inc.	Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009001214A2 (en)	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en)	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
CA2717529A1 (en)	2008-03-11	2009-09-17	Cellzome Limited	Sulfonamides as zap-70 inhibitors
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20110182881A1 (en)	2008-06-26	2011-07-28	Dana-Farber Cancer Institute, Inc.	Signature and determinants associated with metastasis and methods of use thereof
JP5645839B2 (ja)	2009-03-05	2014-12-24	武田薬品工業株式会社	Ｃｄｃ７キナーゼ阻害剤としてのチエノピリミジン
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en)	2009-09-11	2011-04-01	Bayer Schering Pharma Ag	Substituted (heteroarylmethyl) thiohydantoins
US20120238533A1 (en)	2009-09-11	2012-09-20	Bayer Pharma Aktiengesellschaft	(Heteroarylmethyl) Thiohydantoins as anticancer drugs
AR079343A1 (es)	2009-12-21	2012-01-18	Lilly Co Eli	Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

2011
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 SM SM20190385T patent/SMT201900385T1/it unknown
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja active Application Filing
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active Active
- 2011-02-16 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
- 2011-02-16 PH PH1/2012/501650A patent/PH12012501650B1/en unknown
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
2014
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
2019
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown

Also Published As

Publication number	Publication date
KR20130001246A (ko)	2013-01-03
LT2540728T (lt)	2019-06-25
SMT201900385T1 (it)	2019-09-09
JPWO2011102399A1 (ja)	2013-06-17
CA2790284C (en)	2019-01-08
US20160310494A1 (en)	2016-10-27
US8933069B2 (en)	2015-01-13
US20130029969A1 (en)	2013-01-31
PH12012501650B1 (en)	2018-11-07
US20150158882A1 (en)	2015-06-11
EP2540728A4 (en)	2013-11-06
CY1121792T1 (el)	2020-07-31
EP2540728A1 (en)	2013-01-02
WO2011102399A1 (ja)	2011-08-25
US20140235615A1 (en)	2014-08-21
JP5689454B2 (ja)	2015-03-25
MX2012009602A (es)	2012-12-17
US8722660B2 (en)	2014-05-13
AU2011216404A1 (en)	2012-09-20
CL2012002250A1 (es)	2013-02-08
TN2012000401A1 (en)	2014-01-30
CN102844320B (zh)	2016-03-23
BR112012020311A2 (pt)	2017-03-01
HRP20190947T1 (hr)	2019-07-26
US9655900B2 (en)	2017-05-23
RS58796B1 (sr)	2019-07-31
GEP20146202B (en)	2014-11-25
MX353500B (es)	2018-01-16
PL2540728T3 (pl)	2019-09-30
DK2540728T3 (da)	2019-05-13
SG183304A1 (en)	2012-09-27
US9388195B2 (en)	2016-07-12
ECSP12012160A (es)	2013-03-28
DOP2012000224A (es)	2013-01-31
CR20120448A (es)	2012-11-13
EA020724B1 (ru)	2015-01-30
NZ602089A (en)	2014-05-30
BR112012020311B1 (pt)	2019-01-29
MY164776A (en)	2018-01-30
CN102844320A (zh)	2012-12-26
KR101735868B1 (ko)	2017-05-15
US20140228352A1 (en)	2014-08-14
SI2540728T1 (sl)	2019-06-28
PH12012501650A1 (en)	2012-10-22
EP3533797B1 (en)	2023-12-20
ES2733221T3 (es)	2019-11-28
EA201290800A1 (ru)	2013-03-29
EP3533797A1 (en)	2019-09-04
IL221442A0 (en)	2012-10-31
CO6592104A2 (es)	2013-01-02
PE20130184A1 (es)	2013-03-09
ME03410B (me)	2020-01-20
MA34064B1 (fr)	2013-03-05
US20170209452A1 (en)	2017-07-27
EP2540728B1 (en)	2019-04-10
CA2790284A1 (en)	2011-08-25
PT2540728T (pt)	2019-07-11
AU2011216404B2 (en)	2016-04-07
US8921354B2 (en)	2014-12-30

Publication	Publication Date	Title
DK2540728T3 (da)	2019-05-13	Heterocyklisk forbindelse
BR112013009935C8 (pt)	2017-09-19	compostos
BR112013003753A2 (pt)	2016-05-31	compostos
EP2604601A4 (en)	2013-11-27	HETERO RING CONNECTION
PL2614063T3 (pl)	2016-06-30	Podstawione imidazopirydazyny
EP2738170A4 (en)	2014-12-31	HETEROCYCLIC CONNECTION
DK2648516T3 (da)	2019-01-02	Substituerede pyridinon-pyridinylforbindelser
BR112012028556A2 (pt)	2014-04-01	Indóis
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
CR20130111A (es)	2013-05-29	Triazina-oxidiazoles
DE10170954T8 (de)	2013-04-25	Mikrowellendruckgarer
DK2590974T3 (da)	2014-07-28	Tetrahydropyridopyrimidinderivater
EP2622917A4 (en)	2014-07-09	POSITIONING
DK2596210T6 (da)	2021-11-01	Boring
EP2622916A4 (en)	2014-07-09	POSITIONING
CO6801726A2 (es)	2013-11-29	Compuestos
PT2626350E (pt)	2015-08-03	Composto de ciclopropano
DK2649070T3 (da)	2014-10-13	Triazolpyridinforbindelser
IL225895A0 (en)	2013-06-27	Anti-diabetic compounds
BR112013010643A2 (pt)	2016-08-09	compostos heterocíclicos
BR112012026803A2 (pt)	2016-07-12	composto
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DE102010019119B8 (de)	2013-01-31	Cuttermesser
DE102010012963A8 (de)	2012-02-16	Bohrwerkzeug